CT:BHC Bausch Health Companies Inc
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol BHC.
This company has cross-listed shares that trade in the U.S. as the symbol BHC.
9.92 CAD
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Drug Manufacturers-Specialty &
Index country: Canada
Country of incorporation: Canada
IPO date: 12/31/1999
Stock exchange: Toronto Stock Exchange
Exchange country: Canada
Market cap: 4,699,239,936 CAD
Current dividend yield: 0.00%
Sedol: BFFY852